Anticoagulant-related bleeding in patients with heart failure in combination with chronic obstructive pulmonary disease and atrial fibrillation. Experience with Idarucizumab

Anticoagulant-related bleeding in patients with heart failure in combination with chronic obstructive pulmonary disease and atrial fibrillation. Experience with Idarucizumab

Aim. To study the characteristics of direct oral anticoagulant-related bleeding in patients with heart failure in combination with chronic obstructive pulmonary disease (COPD) and atrial fibrillation. To show the efficacy of idarucizumab in complex therapy of severe gastrointestinal bleeding caused...

Full description

Bibliographic Details
Main Authors:	L. A. Shpagina, O. S. Kotova, I. S. Shpagin, E. M. Loktin, A. A. Rukavitsyna, T. S. Flyagin, T. M. Smarzh, N. V. Kamneva, D. A. Gerasimenko, E. V. Anikina, A. V. Ponomareva
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2020-06-01
Series:	Российский кардиологический журнал
Subjects:	direct oral anticoagulants bleeding idarucizumab
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/3921

Similar Items

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
by: Jameel Abdulrehman, et al.
Published: (2021-07-01)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
by: Sié P
Published: (2016-05-01)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
by: Proietti M, et al.
Published: (2018-08-01)

Safety of direct oral anticoagulants in patients with atrial fibrillation and high risk of stroke (review of literature)
by: E. I. Baranova, et al.
Published: (2020-02-01)

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
by: Hu TY, et al.
Published: (2016-02-01)

Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy
by: Masahiro Yasaka, et al.
Published: (2020-05-01)

Idarucizumab in High-risk Thoracic Surgery
by: R L�pez Vilella, et al.
Published: (2018-04-01)

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study
by: Masahiro Yasaka, et al.
Published: (2020-03-01)

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
by: Valentin Held, et al.
Published: (2016-10-01)

The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports
by: Tomić Milan
Published: (2020-01-01)

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
by: Mathias Ströhle, et al.
Published: (2021-04-01)

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran
by: Giannandrea D, et al.
Published: (2019-05-01)

Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
by: Sergio Agosti, et al.
Published: (2017-08-01)

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting
by: Nicolas Gendron, et al.
Published: (2020-12-01)

New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
by: E. I. Baranova
Published: (2018-11-01)

Management of major bleeding in patients treated with direct oral anticoagulants: from experience to standardized protocols
by: Sara Mascia, et al.
Published: (2020-06-01)

The new way of Dabigatran reversal – Idarucizumab
by: Erwin Ciechański, et al.
Published: (2019-02-01)

Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study)
by: Esme Ekizoğlu
Published: (2018-06-01)

Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
by: Gorana Vukorepa, et al.
Published: (2020-01-01)

Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications
by: Maurizio Tala, et al.
Published: (2018-09-01)

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
by: Waldemar Kafke, et al.
Published: (2016-06-01)

Idarucizumab (Praxbind) for reversal of pradaxa prior to emergent repair of contained ruptured transverse arch aneurysm
by: Erol Vahit Belli, et al.
Published: (2017-01-01)

Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01)

How to effectively reverse life-thretening effects of non-vitamin K oral anticoagulants?
by: Łukasz Wołowiec, et al.
Published: (2017-02-01)

Idarucizumab for a traumatic head injury patient taking dabigatran
by: Shuhei Maruyama, et al.
Published: (2018-10-01)

HOW TO REDUCE GASTROINTESTINAL BLEEDING RISK ON ANTICOAGULATION THERAPY IN NON-VALVULAR ATRIAL FIBRILLATION?
by: E. I. Baranova, et al.
Published: (2017-11-01)

The first experience with thrombolytic therapy for cerebral infarction in the Russian Federation after the use of idarucizumab
by: E. V. Pudov, et al.
Published: (2020-02-01)

Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
by: António Tralhão, et al.
Published: (2017-09-01)

New oral anticoagulants and their reversal agents
by: Crista L. Laslo, et al.
Published: (2018-10-01)

Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
by: Stephanie A. Kustos, et al.
Published: (2019-10-01)

Hemorragia digestiva grave de origen oscuro resuelta con idarucizumab
by: Enrique Rodríguez-de-Santiago, et al.

The (Fab)ulous Destiny of Idarucizumab: Highlighting Its Interference with Urine Protein Immunofixation
by: Nicolas Gendron, et al.
Published: (2019-07-01)

Reversal of direct oral anticoagulants
by: Almegren M
Published: (2017-07-01)

Laboratory bleeding predictors in elderly patients with atrial fibrillation taking direct oral anticoagulants
by: M. A. Gabitova, et al.
Published: (2020-01-01)

Specific Antidotes for Direct Oral Anticoagulants in Life-Threatening Bleeding
by: A. B. Sumarokov, et al.
Published: (2019-01-01)

Direct oral anticoagulants: first airbag
by: A. N. Sokolova, et al.
Published: (2019-04-01)

Oral anticoagulant therapy in atrial fibrillation older patients with previous bleeding
by: Mario Bo, et al.
Published: (2020-03-01)

Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations
by: Kazunori Toyoda, et al.
Published: (2018-09-01)

Clinical protocols for oral anticoagulant reversal during high risk of bleeding for emergency surgical and nonsurgical settings: a narrative review
by: Carlos Galhardo, Jr., et al.
Published: (2021-07-01)

Reversión de anticoagulantes orales directos: una perspectiva desde Urgencias
by: Mateo Zuluaga Gómez, et al.
Published: (2020-11-01)